Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial

<h4>Importance</h4> <p>Developing effective vaccines against Ebola virus is a global priority.</p> <h4>Objective</h4> <p>To evaluate an adenovirus-type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV) and a modified vaccinia Ankara vector vaccine,...

Full description

Bibliographic Details
Main Authors:	Milligan, I, Gibani, M, Sewell, R, Clutterbuck, E, Campbell, D, Plested, E, Nuthall, E, Voysey, M, Silva Reyes, L, McElrath, M, De Rosa, S, Frahm, N, Cohen, K, Shukarev, G, Orzabal, N, van Duijnhoven, W, Truyers, C, Bachmayer, N, Splinter, D, Samy, N, Grazia Pau, M, Schuitemaker, H, Luhn, K, Callendret, B, Van Hoof, J, Douoguih, M, Ewer, K, Angus, B, Pollard, A, Snape, M
Format:	Journal article
Published:	American Medical Association 2016

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial

Similar Items